CD274 and melanoma: We developed NDs loaded with PD-1/PD-L1 inhibitor (BMS202) to target melanoma cells, enabling the blockade of the interaction between PD-L1 and its receptor and the subsequent enhancement of the immune response leading to destruction of the melanoma cells.